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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(AHSCT) is a potentially curative treatment for a variety of
hematologic malignancies. The major complications of
AHSCT include graft failure, opportunistic infections,
leukemic relapse, and graft-versus-host disease (GVHD).
The incidence of the ﬁrst 3 complications is diminished by
the presence of mature donor T cells in the transplant
inoculum and by the breadth and speed of T-cell reconstitu-
tion. Unfortunately, the transplantation of mature alloreactive
donor T cells also directly induces the latter complication of
acute GVHD. Traditional, fully myeloablative conditioning
originally was an attempt to cure malignancy by facilitating
the delivery of dose-intensified anticancer therapy. It was
also necessary for these regimens to be immunoablative to
avoid rejection of the allogeneic stem cells [1-3]. Over the
last 15 years, fully myeloablative conditioning has been
combined with T-cell depletion of the donor inoculum, in
an attempt to decrease the incidence and severity of GVHD.
However, T-cell depletion can contribute to significant
delays in immune reconstitution and increased rates of graft
failure and, in some diseases, relapse [4-8]. Thus, it has
become clear that one major objective for improving the
outcome of AHSCT is to achieve rapid T-cell reconstitu-
tion, without GVHD.
The recent use of nonmyeloablative pretransplantation
conditioning regimens as an alternative to myeloablative
treatments has also resulted in durable engraftment of
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Nonmyeloablative pretransplantation conditioning regimens have resulted in durable engraftment of allogeneic
hematopoietic stem cells. In contrast to conventional fully myeloablative approaches, nonmyeloablative regimens
are associated with a marked reduction of morbidity and mortality in the early posttransplantation period. Conse-
quently, such reduced-intensity transplantation approaches can be used in older and frailer patients who would not
tolerate fully ablative regimens. However, it is currently unclear how this radically different transplantation strategy
affects immunological reconstitution. To address this important issue, we used T-cell receptor Vβ spectratype
analysis to examine the distribution of complementarity-determining region 3 (CDR3)-size bands as a measure of
the complexity of the redeveloping T-cell repertoire. For this study, we evaluated the T-cell repertoire of 9 patients
receiving T-cell replete, matched unrelated donor transplants following fully ablative or nonmyeloablative condi-
tioning regimens. All 4 of the myeloablative and 2 of the nonmyeloablative patients received bone marrow, whereas
3 other nonmyeloablative patients received peripheral blood stem cells. The results of the spectratype analysis
demonstrated that the patients who received nonmyeloablative conditioning together with either bone marrow or
peripheral blood stem cells exhibited more rapid reconstitution of T-cell repertoire complexity.
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allogeneic stem cells in most patients [9,10]. Nonmyeloab-
lative conditioning regimens typically consist of low-dose
radiation (2-4 Gy) or alkylating agents combined with
purine analogs, such as fludarabine or 2-chlorodeoxy-
adenosine [9-12]. In contrast to fully myeloablative
approaches, nonmyeloablative conditioning is associated
with a reduction in morbidity and mortality in the peri-
transplantation period [13]. Consequently, these approaches
have been applied to older patients and patients with
comorbid medical problems such as organ damage due to
advanced disease and/or heavy previous chemoradiother-
apy. Nonmyeloablative conditioning may be associated with
a delayed onset of acute GVHD compared to myeloablative
approaches (R. Champlin, MD, oral communication) and,
by reducing early mortality, may potentially lead to
improved disease-free survival [12]. Therefore, in light of
these encouraging results, it is important to understand
how these 2 transplantation strategies differ with regard
T-cell repertoire reconstitution.
The extensive complexity and diversity of the T-cell
repertoire is partially determined by rearrangement and
fusion between the V, D, and J segments. This rearrangement
combined with random insertion and deletion of junctional
nucleotides determines the size of the complementarity-
determining region 3 (CDR3) of the T-cell receptor (TCR)
[14]. The end result of this process is the generation of a large
heterogeneous pool of CDR3-size lengths that differ by 3
nucleotides within each TCR Vβ family. The CDR3 region is
centrally involved in antigen recognition by forming the con-
tact site between the TCR and the antigenic peptides bound
by the major histocompatibility complex molecules [15]. The
CDR3 region thus acts as a ﬁngerprint for the T-cell progeny
bearing it and, when observed in totality, directly reﬂects the
complexity and diversity of the T-cell repertoire. Polymerase
chain reaction (PCR)-based TCR Vβ CDR3-size spectratyp-
ing analysis is a highly sensitive tool for examining TCR
diversity and can be used as a means of characterizing the
complexity of T-cell repertoire reconstitution following
AHSCT [16-18]. In general, spectratype analysis generates
between 8 and 10 different size classes of CDR3-length PCR
products for each Vβ family. The more complex the T-cell
repertoire, the greater is the number of different-sized PCR
products generated.
In this study, we used CDR3 spectratype analysis to
compare the reconstitution of T-cell repertoire complexity
of 9 patients, who underwent allogeneic bone marrow
transplantation (BMT) or peripheral blood stem cell trans-
plantation (PBSCT) from matched unrelated donors with-
out T-cell depletion. Four patients received BMT following
fully myeloablative treatment (MYELO). Five patients
underwent transplantation following nonmyeloablative
conditioning (NONMYELO), of whom 2 received BMT
and 3 received PBSCT. The results indicated that, in the
MYELO group, 15% to 35% of the Vβ family spectratypes
observed exhibited repertoire complexities ≥85% of their
donors. In contrast, 89% to 100% of the Vβ family spectra-
types observed in the NONMYELO group had complexities
≥85% of their donors. Because it appears that nonmyeloab-
lative conditioning, together with use of either BMT or
PBSCT, allows better reconstitution of the T-cell reper-
toire complexity, it is likely to afford advantages regarding
the avoidance of opportunistic infections and, potentially,
leukemic relapse.
MATERIALS AND METHODS
Patients and Donors
Nine patients, aged 30 to 79 years (median, 49 years),
received AHSCT from unrelated volunteer donors. Four
patients, designated M1 to M4, received transplants following
a myeloablative regimen consisting of total body irradiation
(12 Gy) and cytoxan (60 mg/kg × 2). Five patients, designated
NM5 to NM9, received transplants following a nonmye-
loablative regimen consisting of ﬂudarabine (20-30 mg/m2
per day × 5) (days –6 through –2), cytosine-arabinoside
(2 g/m2 × 3) (days –6, –4, –2), and cyclophosphamide
(60 mg/kg × 2) (days –5 and –3). All patients were serologi-
cally typed for HLA-A, -B, and -C and molecularly typed
for DR and DQ.
GVHD Prophylaxis and Treatment
All 9 patients received cyclosporine A (CSA)-based pro-
phylaxis for GVHD with doses adjusted based on blood lev-
els. All 4 MYELO recipients also received a CD4 peptide
analogue, 802-2, at a dosage of 1 to 2.5 mg/kg per day for 4
doses on days 1, 3, 5, and 7 after transplantation [19]. In
addition, 3 of the MYELO patients received methotrexate
(MTX) (15 mg/m2 on day 1 and 10 mg/m2 on days 3, 6, and
11) and 1 received mycophenolate mofotil (MMF), 1 g twice
a day (BID) for 28 days as part of their GVHD prophylaxis.
The 5 NONMYELO patients also received MMF, 1 g BID
for 28 days, and 2 patients received Remicade (10 mg/kg on
days 0, 7, and 14) and Zenapax (1 mg/kg on days 3, 7, 11,
and 14), as well.
Blood Samples
Peripheral blood lymphocytes (PBLs) were enriched
from peripheral blood samples by centrifugation over
Ficoll-histopaque, and solubilized in Ultraspec (Biotex Lab-
oratories, Houston, TX). Vβ spectratype analysis of PBL
obtained from the donors at the time of transplantation
served as our reference point for full repertoire complexity
and was used as the standard of comparison for the patient
samples. Subsequent blood samples were drawn from the
recipients, and spectratype analysis was performed at the
time points shown below. At the time of the spectratype
analysis, 8 of the 9 patients exhibited 100% and the ninth
patient exhibited 94% donor chimerism as determined by
molecular analysis of short tandem repeats [17].
CDR3-Size Spectratype Analysis
Total RNA was isolated from Ultraspec samples and
cDNA was prepared as previously described [18,20]. Semi-
nested PCR was performed using a panel of human Vβ
sense oligoprimers and 2 Cβ antisense oligoprimers [21]. The
second Cβ antisense oligoprimer was internal to the ﬁrst Cβ
antisense oligoprimer and was synthesized and ﬂuorescently
labeled using an Applied Biosystems apparatus (Foster City,
CA) provided by the KCI Nucleic Acid Facility. The PCR
products were run on a sequencing gel and analyzed by the
Genotyper Genescan software program (Applied Biosys-
tems). This approach allowed direct comparison of the TCR
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Vβ repertoire reconstitution in MYELO versus NON-
MYELO recipients.
Spectratype Complexity Index
The recipient complexity index within a Vβ family was
determined as a percentage of the number of peaks in its
spectratype histogram compared to the number of peaks in
the corresponding donor Vβ family spectratype histogram.
Any Vβ family with a complexity index of ≥85% was consid-
ered to be fully complex. Histogram peaks were deﬁned by
the Genotyper Genescan software analysis program
(Applied Biosystems).
Monoclonal Antibodies and Flow Cytometric Analysis
Blood for ﬂow cytometric analysis was collected in ster-
ile tubes containing heparin or acid-citrate-dextrose (ACD)
as anticoagulants. White blood counts on the specimens were
performed using a Coulter counter, and aliquots containing
5 × 105 white cells were distributed into tubes containing the
appropriate Simultest antibodies (Becton Dickinson, Moun-
tain View, CA) to human leukocyte subpopulations. After a
10-minute incubation, 2 mL of fluorescence-activated cell
sorter (FACS) lysing solution (Becton Dickinson) was
added, followed by another 10-minute incubation. Cells
were then washed twice in phosphate-buffered saline (PBS)
containing 0.1% sodium azide and 2% mouse serum, once
in PBS with 0.1% sodium azide without mouse serum, and
ﬁnally ﬁxed in a solution of 2% formalin in PBS. Cells were
analyzed on a FACScan (Becton Dickinson) ﬂow cytometer.
The entire white cell population was analyzed, and absolute
numbers of CD4 and CD8 T cells/mL of blood were calcu-
lated as the product of the white blood count times the per-
centage of CD3+CD4+ and CD3+CD8+ cells within the total
white blood cell subpopulation.
Statistical Analysis
Data were analyzed by the nonparametric rank-sum
analysis of Wilcoxon. P values of <.05 were considered sta-
tistically signiﬁcant.
RESULTS
Patient Characteristics and GVHD Status
The patients’ ages, underlying diseases, and the HLA
disparities between donor and recipient are illustrated in
Table 1. Eight patients developed acute GVHD. The ninth
patient did not develop acute GVHD but developed exten-
sive chronic GVHD. Although patient numbers were very
small, the overall severity of GVHD did not differ between
the MYELO and NONMYELO patients, ranging from
mild to severe in both groups (Table 1). However, it
appeared that the median onset of GVHD was delayed in
the NONMYELO patients, at 32 days (range, 9-171 days)
in contrast to 17 days (range, 10-17 days) for the MYELO
group, although this difference attained only marginal sig-
nificance (P = .07). All patients developing acute GVHD
received corticosteroids at initial doses of 2 mg/kg of sol-
umedrol or prednisone and had their CSA continued. Three
recipients of NONMYELO transplants had their MMF
continued beyond day 28. Additional agents for treatment of
GVHD were added based on clinical response as shown in
Table 1. The treatment agent for the patient with chronic
GVHD was converted from CSA to tacrolimus.
Donor Chimerism
To evaluate the reconstitution of donor T-cell repertoire
complexity, it was necessary to demonstrate that near-
complete T-cell donor chimerism had been established.
Molecular analysis was carried out on the CD3+ cell population
Table 1. Patient Characteristics and Clinical Outcome*
Acute GVHD
Patient Disease Age, y HLA Disparity Prophylaxis Treatment Day of Onset Grade
M1 CML 36 R: A74, Cw2 CSA, MTX, CD4 peptide CSA, steroids, Zenapax, 10 III
D: A32, Cw– MMF, ATG
M2 CML 43 None CSA, MMF, CD4 peptide CSA, steroids, Zenapax 15 II
M3 ALL 30 R: A32, Cw6, CSA, MTX, CD4 peptide CSA, steroids, Zenapax, MMF, 11 IV
DRB3 0201 ATG, OKT3, Rapamycin
D: A30, Cw2, 
DRB3 0202
M4 ALL 53 None CSA, MTX, CD4 peptide CSA, steroids 17 I
NM5 AML 61 None CSA, MMF, Zenapax, CSA, steroids, MMF, PUVA 34 I
Remicade
NM6 NHL 49 R: Cw–, CSA, MMF, Zenapax, CSA, steroids, Zenapax 32 II
DQB1 0602 Remicade Remicade
D: Cw7, 
DQB1 02XX
NM7 AML 61 R: DRB4– CSA, MMF CSA, steroids 24 I
D: DRB4 01XX
NM8 AML 79 R: DRB1 1104 CSA, MMF CSA, steroids, Zenapax, MMF, 9 IV
D: DRB1 1101 ATG, OKT3, Rapamycin
NM9 NHL 40 None CSA, MMF CSA, steroids, MMF, 171 0 (Acute;  
Tacrolimus (Chronic only) chronic limited)
*CML indicates chronic myelogenous leukemia; R, recipient; D, donor; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia;
NHL, non-Hodgkin’s lymphoma;
TCR Vβ Repertoire Reconstitution
659B B & M T
of PBL and bone marrow aspirates from all patients. Near-
complete to full donor chimerism (94% for 1 NON-
MYELO patient and 100% for the other 8 patients) was
demonstrated in the CD3+ cell population between days 17
and 50 (median and mean, day 32) posttransplantation for
all patients (Table 2). There was no signiﬁcant difference in
the establishment of T-cell donor chimerism between the
MYELO and NONMYELO patients (P > .20).
Flow Cytometric Analysis
Flow cytometric analysis of the CD3+/CD4+ and
CD3+/CD8+ T-cell populations from the MYELO and
NONMYELO patient groups was carried out to evaluate
overall T-cell reconstitution. For each patient, the results of
the phenotyping studies temporally closest to the spectratype
analyses are listed in Table 2. Double staining of peripheral
mononuclear cell samples with monoclonal antibodies to
CD3 and CD4 revealed that both patient groups exhibited
comparable absolute numbers of CD4+ T cells, albeit with
wide variability, depending on the time point post-AHSCT
of the test (Table 2). The range of numbers of CD4+ T cells
in the MYELO group was between 4.79 and 185.6 cells/µL,
compared to 15.6 to 132.3 cells/µL in the NONMYELO
group. There was also no observable distinction between the
2 groups in the number of CD8+ T cells found, except for the
unusually high level (974.5 cells/µL) in patient #1 of the
MYELO group, who developed a posttransplantation
Epstein-Barr virus lymphoma. Otherwise, the numbers of
CD8+ T cells detected in 2 of the remaining MYELO
patients (11.6-61.4 cells/µL) and 4 of the NONMYELO
patients (46.8-248.26 cells/µL) were well within expectation
for the time points at which they were obtained [22].
Determination of Complexity Index by CDR3-Size
Spectratype Analysis
CDR3-size spectratype analysis was used to examine the
complexity of 24 Vβ families from every donor-recipient
pair, as described in “Materials and Methods.” All spec-
tratype analyses performed after transplantation were con-
ducted on patient PBLs at time points after donor
chimerism had been demonstrated. Representative spec-
tratype analyses for 3 Vβ families can be seen in Figures 1
and 2 for the MYELO and NONMYELO groups, respec-
tively. The complexity index for each resolvable Vβ family
was determined, as described in “Materials and Methods,”
by comparing the donor and patient spectratype histograms.
The results, summarized in Table 3, indicated that 15% to
35% of all Vβ families resolved in the MYELO patients
were fully complex. In contrast, a signiﬁcantly higher per-
centage of the Vβ family spectratypes resolved in the NON-
MYELO group were fully complex (89%-100%; P < .01).
All 4 MYELO and 2 of the 5 NONMYELO patients
received BM, whereas the 3 other NONMYELO patients
received PBSC. No difference was noted in the level of
complexity reconstitution between the NONMYELO
patients receiving BM and those receiving PBSC.
DISCUSSION
Myeloablative conditioning regimens for AHSCT are
typically associated with a high degree of morbidity and
mortality, which has limited the application of AHSCT pri-
marily to younger patients in relatively good general health.
Such aggressive preparative treatments were originally
designed to eradicate malignant cells by allowing dose-
intensified chemotherapy and radiotherapy to be adminis-
tered. At the same time, it was necessary for regimens to be
immunoablative as well, to ensure engraftment of AHSC.
Over the years, extensive experimental and clinical data have
supported the relationship between donor-derived T cells
and a graft-versus-leukemia (GVL) effect [23-27]. Increased
appreciation of the role of GVL in controlling or curing
residual malignancy after AHSCT has led to the develop-
ment of new therapeutic approaches to more directly use
GVL, including the use of donor lymphocyte infusions and,
more recently, nonmyeloablative conditioning regimens
[9,11,12]. The focus of these nonmyeloablative approaches
is to provide sufﬁcient immunosuppression to allow engraft-
ment of allogeneic lymphocytes and stem cells, such that
GVL rather than dose intensity would constitute the pri-
mary therapeutic modality.
After AHSCT, reconstitution of the T-cell population
can occur via thymic dependent pathways as well as periph-
eral expansion of donor-derived memory cells [28-30]. These
T cells can persist on a long-term basis and are thereby avail-
able to generate immune responses when challenged by an
appropriate antigen [31-34]. The decreased toxicity associ-
ated with nonmyeloablative conditioning regimens may also
enhance the ability of the recipient thymus to support differ-
entiation of de novo–derived T cells of donor origin compared
Table 2. Molecular and Flow Cytometric Analysis of Recipient PBL*
Day Posttransplantation When Sample Was Obtained
Patient Donor Chimerism Spectratype Analysis Flow Cytometry CD4+ T cells/µL CD8+ T cells/µL
M1 33 69 60 185.6 974.5
M2 32 129 102 46.2 61.4
M3 31 58 27 4.8 11.6
M4 35 39 ND ND ND
NM5 28 28 28 68.7 74.8
NM6 28 57 57 15.6 46.8
NM7 32 38 64 88.6 248.3
NM8 17 21 ND ND ND
NM9 50 105 132 132.3 143.9
*ND indicates not determined.
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to more toxic regimens, which may produce more substantial
thymic injury. In either case, the capacity of the donor-
derived T-cell population to respond to foreign antigens is
likely to correlate with the extent and complexity of the
T-cell repertoire existing in the recipient at the time of
infectious challenge. Recently, Roux et al. have demonstrated
that unmanipulated AHSCT developed a more complex
repertoire reconstitution than T-cell–depleted donor inocu-
lum in fully myeloablated transplantation patients [35]. Our
current study, however, represents the ﬁrst of its kind to use
Figure 1. CDR3-size spectratype analysis of PBL from MYELO donor-recipient pairs. Reverse transcription (RT)-PCR products using Vβ speciﬁc
primers were generated from PBL of donors at the time of transplantation and their respective recipients after transplantation. The spectratype
analysis was performed as described in “Materials and Methods.” Three representative Vβ family spectratype histograms are shown for each pair,
demonstrating less complexity in the patient samples.
Figure 2. CDR3-size spectratype analysis of PBL from NONMYELO donor-recipient pairs. RT-PCR products using Vβ speciﬁc primers were
generated from PBL of donors at the time of transplantation and their respective recipients after transplantation. The spectratype analysis was per-
formed as described in “Materials and Methods.” Three representative Vβ family spectratype histograms are shown for each pair, demonstrating
equal complexity in the patient samples.
TCR Vβ Repertoire Reconstitution
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Vβ spectratype analysis to examine the T-cell repertoire
reconstitution between patients receiving fully myeloablative
and nonmyeloablative pretransplantation conditioning with
unmanipulated transplant inocula.
Molecular analysis indicated that there were no signiﬁ-
cant differences in the establishment of donor chimerism in
the recipients, despite the different conditioning regimens of
the 9 patients in this study and whether they received PBSCT
or BMT. These results are in agreement with other investiga-
tions that have reported the establishment of full donor
chimerism early after transplantation following nonmyeloab-
lative conditioning [36,37]. The establishment of full donor
chimerism prior to the spectratype analysis was important to
ensure that the results were reﬂective of donor-derived T-cell
reconstitution rather than residual host elements.
CDR3-size spectratype analysis provided evidence that a
more complex Vβ repertoire was reconstituted early after
nonmyeloablative conditioning, as compared with that
observed in patients who received fully myeloablative condi-
tioning. In comparing the 2 groups, we defined full com-
plexity as a spectratype demonstrating at least 85% of the
complexity of the transplant donor. However, the 2 groups
of patients are statistically different from one another even
if the definition of full complexity is made less stringent
(P = .03 for a cutoff ≥75%) or more stringent (P < .001 for
a cutoff ≥95%).
Because nonmyeloablative approaches more commonly
use peripheral blood rather than marrow as the source of
donor stem cells and lymphocytes, we originally hypothe-
sized that the difference in repertoire diversity we observed
might reﬂect the stem cell source rather than the condition-
ing regimen. We considered this possibility because periph-
eral stem cell products typically contain larger numbers of
stem cells and mature lymphocytes in contrast to BM, both
of which might accelerate T-cell reconstitution. However,
analyses of the NONMYELO patients who received BM
grafts reconstituted their repertoire to the same extent as
those receiving PBSC. This observation argues that differ-
ences in the conditioning regimen exert more profound
effects on immune reconstitution than do differences in the
stem cell source or number of infused T cells. Although
younger patients might be expected to immunoreconstitute
faster than older ones, the NONMYELO group of patients
was slightly older than the MYELO group, indicating that
patient age also does not explain the differences noted.
We also considered the impact of differences in GVH
prophylaxis on our observations. At the present time, cyclo-
sporine and MMF represent a gold standard for GVH and
rejection after NONMYELO regimens, whereas cyclo-
sporine and MTX represent a similar standard for conven-
tional grafts. Patients in both treatment groups received
additional agents designed to eliminate activated lympho-
cytes early after transplantation (CD4 peptide and zenapax).
Although GVHD prophylaxis was not identical in the
2 patient groups, the differences here are far smaller than
the differences in conditioning regimen and stem cell
source. Both CD4 peptide and zenapax would be expected
to remove only those T cells activated early after BMT from
exposure to host alloantigens triggering GVHD [38,39].
Neither would therefore be expected to globally alter the
T-cell repertoire. Moreover, the use of cyclosporine and MMF
has been shown to be synergistic in preventing rejection of
Table 3. Spectratyping Results*
Vβ M1 M2 M3 M4 NM5 NM6 NM7 NM8 NM9
1 – + – + + + + + ND
2 – + – – + + + + +
3 – – + + + + + + +
4 – + – – + + + + +
5 – + ND + + + + + +
6 – – ND – + + ND ND +
7 – – – ND + ND ND + ND
8 – ND – – + + ND + +
9 – + – + + + + + +
10 ND ND ND ND + + ND + ND
11 – – – – + + + + +
12 – ND ND – + + ND ND +
13 – – – – + ND + + +
14 – ND – + + + + + +
15 + + ND – + + + + +
16 – – – – + + + + +
17 + – – + + + + + +
18 – – ND + + ND ND ND ND
19 – – – – + – + + +
20 ND ND ND ND + ND ND ND +
21 + – + – + ND + + ND
22 – ND ND – + + ND ND +
23 ND – + – + – + + +
24 – ND ND ND + ND ND ND +
% 15 35 20 35 100 89 100 100 100
*– indicates not full complexity; +, full complexity; ND, not determined; %, total percent of complex Vβ families for each patient.
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canine marrow in sublethally irradiated animals [40]. Thus,
one would anticipate that this regimen would be, if any-
thing, more rather than less immunosuppressive and should
have delayed, not accelerated, immune recovery in the
NONMYELO group. Finally, patients receiving lymphoab-
lative agents such as antithymocyte globulin (ATG) or
OKT3 did not behave as outliers in their respective groups,
again suggesting that our results reflect the conditioning
regimen, rather than GVHD prophylaxis and/or treatment.
It is not clear whether the enhanced complexity
observed in the NONMYELO group was due to peripheral
expansion of the donor T cells or to de novo thymic pro-
duction. However, the majority of samples were collected at
less than 2 months posttransplantation and might therefore
be too early to represent reconstitution via the thymus [41].
More deﬁnitive evidence to determine reconstitution path-
ways could be obtained using TCR rearrangement excision
circle (TREC) analysis [42,43] and this method is under fur-
ther investigation. Whether reconstitution occurs via
thymic selection or peripheral expansion, there is still
potential for adverse impact from fully myeloablative regi-
mens. Tissue damage from total body irradiation and other
aggressive preconditioning is more likely to damage the
stromal elements of the thymus as well as the BM, sec-
ondary lymphoid organs, and other tissues in which periph-
eral expansion takes place. These elements are necessary to
contribute to the appropriate microenvironment required
for T-cell development and expansion [44,45]
With regard to the overall T-cell number in peripheral
blood, it is not unreasonable to have determined these num-
bers to be similar between the MYELO and NONMYELO
patients. In an earlier study comparing immune reconstitu-
tion between T-cell–depleted and conventional AHSCT,
both with myeloablative preconditioning, the T-cell counts
were equivalent during the first 100 days [22]. However,
there was a delay in the recovery of T-cell proliferative
responses from the T-cell–depleted grafts, suggesting the
presence of additional qualitative rather than quantitative
differences in the T-cell repertoire and T-cell function,
including more limited repertoire complexity. Of note,
patient M1, whose total T-cell counts were the highest in
the study (1160.1 cells/µL) but who exhibited the lowest
complexity index (15%), may represent an example of such
qualitative versus quantitative defects.
The trend for a delayed onset of GVHD noted in the
recipients of nonmyeloablative transplantations may also be
related to the increased level of T-cell repertoire complexity
observed in these patients. Although GVHD is known to
correlate with an immunosuppressive state and inadequate
T-cell reconstitution, it is often thought that the deﬁciencies
are a consequence of the disease, because of thymic or lym-
phoid target tissue destruction and the presence of inﬂam-
matory cytokines. However, a delay in the reconstitution of
T-cell repertoire complexity could also lead to diminished
numbers of alloreactive immunoregulatory T cells, such as
those marked by CD4+CD25+ expression [46,47]. These
regulatory elements, which may be generated de novo via
the host thymus from donor stem cells, may be more deﬁ-
cient in the less complex T-cell repertoire of the MYELO
patients, thereby allowing GVHD to develop at a faster pace
posttransplantation. Further investigation to address this
hypothesis is needed, once the delayed onset of GVHD in
NONMYELO patients is more firmly established in a
larger number of patients. The possibility also exists that the
delayed onset of GVHD might also relate to the differences
in prophylactic regimens or to the more limited damage to
the tissues from the NONMYELO regimens, such that
immune recognition triggering GVHD occurs in a less
proinﬂammatory environment.
The results of this study demonstrate that nonmyeloab-
lative conditioning together with use of either PBSC or BM
allows for earlier reconstitution of T-cell repertoire com-
plexity. A more complete repertoire is likely to afford advan-
tages with regard to the capacity to mount responses to a
wide range of opportunistic infections and potentially to
leukemic relapse, which may, in turn, improve transplanta-
tion outcome.
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